Print

Purpose

The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Women (regardless of menopausal status) or men ≥18 years of age (or per local regulations). - The participant has confirmed HR+, HER2-, early stage resected invasive breast cancer without evidence of distant metastases. - The participant must have undergone definitive surgery of the primary breast tumor. - The participant must have tumor tissue from breast (preferred) or lymph node for exploratory biomarker analysis available prior to randomization. - Pathologic lymph node involvement and at least one of the following indicating a higher risk of recurrence: - 4 or more positive axillary lymph nodes - Tumor size of at least 5 centimeters - Grade 3 defined as at least 8 points on the Bloom Richardson grading system - Ki-67 index by central analysis of ≥20% on untreated breast tissue - The participant must be randomized within 16 months from the time of definitive breast cancer surgery. - The participant may receive up to 12 weeks of endocrine therapy until randomization following the last non-endocrine therapy (surgery, chemotherapy, or radiation) whichever is last. - Participants must have recovered (grade ≤1) from the acute effects of chemotherapy and radiotherapy and from surgical side effects following definitive breast surgery. - Women of reproductive potential must have a negative blood pregnancy test and agree to use highly effective contraceptive methods. - The participant has a Eastern Cooperative Oncology Group (ECOG) performance status ≤1. - The participant has adequate organ function. - The participant is able to swallow oral medications.

Exclusion Criteria

  • Metastatic disease (including contralateral axillary lymph nodes) or node-negative disease. - Participants with inflammatory breast cancer. - Participants with a history of previous breast cancer, with the exception of ipsilateral ductal carcinoma in situ (DCIS) treated by locoregional therapy alone ≥5 years ago. Participants with a history of contralateral DCIS treated by local regional therapy at any time may be eligible. Participants with a history of any other cancer (except non-melanoma skin cancer or carcinoma in situ of the cervix), unless in complete remission with no therapy for a minimum of 5 years from the date of randomization are excluded. - Females who are pregnant or lactating. - The participant has previously received treatment with any CDK4 and CDK6 inhibitor. - The participant is receiving concurrent exogenous reproductive hormone therapy (for example, birth control pills, hormone replacement therapy, or megestrol acetate). - The participant has previously received endocrine therapy for breast cancer prevention (tamoxifen or aromatase inhibitors) or raloxifene. - The participant has serious preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study. - The participant has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin or sudden cardiac arrest. Any participant with a history of venous thromboembolism (VTE). - The participant has active systemic infections or viral load. - The participant has received an experimental treatment in a clinical trial within the last 30 days or 5 half-lives, whichever is longer.

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
150 mg Abemaciclib + Endocrine Therapy 		Participants received Abemaciclib orally at 150 milligrams (mg) twice daily with at least 6 hours between doses for up to 2 years or until evidence of disease recurrence or other discontinuation criteria were met, whichever occurs first. Endocrine therapy (physicians' choice) standard-of-care was administered according to package label until discontinuation criteria were met.
  • Drug: Abemaciclib
    Administered orally.
    Other names:
    • LY2835219
  • Drug: Standard Adjuvant Endocrine Therapy
    Administered according to label instructions.
Other
Endocrine Therapy 		Endocrine therapy (physicians' choice) standard-of-care was administered according to package label until discontinuation criteria were met.
  • Drug: Abemaciclib
    Administered orally.
    Other names:
    • LY2835219
  • Drug: Standard Adjuvant Endocrine Therapy
    Administered according to label instructions.

More Details

Status
Active, not recruiting
Sponsor
Eli Lilly and Company

Study Contact

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.